Marker Therapeutics to Present at Two Upcoming Investor Conferences
Marker Therapeutics will present at and participate in two upcoming investor conferences.
Marker Therapeutics Reports First Quarter 2019 Operating and Financial Results
Marker Therapeutics reports Q1 earnings.
Marker Therapeutics to Present at the Bank of America Merrill Lynch Health Care Conference
President and Chief Executive Officer, Peter L. Hoang, to present at the 2019 Bank of America Merrill Lynch Health Care Conference.
Non-Engineered T Cells to Prevent or Treat Relapse in Post-Transplant AML/MDS
Infusion with “non-engineered” adoptive T-cell products induced responses in select patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) who had undergone allogeneic hematopoietic cell transplantation (alloHCT) and subsequently relapsed.
